Chinese Journal of Pharmacovigilance ›› 2019, Vol. 16 ›› Issue (4): 244-245.
Previous Articles Next Articles
WANG Xing
Received:2019-05-09
Revised:2019-05-09
Online:2019-04-20
Published:2019-05-09
CLC Number:
WANG Xing. One Case of Exfoliative Dermatitis Induced by Lamotrigine Tablets[J]. Chinese Journal of Pharmacovigilance, 2019, 16(4): 244-245.
| [1] Reid J G, Gitlin M J, Altshuler L L. Lamotrigine in psychiatric disorders[J]. J Clin Psychiatry, 2013, 74(7): 675-84. [2] Clark C T, Klein A M, Perel J M, et al. Lamotrigine dosing for pregnant patients with bipolar disorder[J]. Am J Psychiatry, 2013, 170(11):1240-7. [3] 国家药典委员会. 临床用药须知: 化学和生物制品卷[M]. 2015版. 北京: 中国医药科技出版社, 2017:41. [4] 何心, 张永, 徐进, 等.77例拉莫三嗪不良反应的文献分析[J].中国药物警戒. 2016,13(5): 303-305. [5] Adam J, Pichler W J, Yerly D. Delayed drug hypersensitivity: models of T-cell stimulation[J]. British Journal of Clinical Pharmacology, 2011, 71(5):701-707. [6] Wang X Q , Xiong J , Xu W H , et al. Risk of a lamotrigine-related skin rash: Current meta-analysis and postmarketing cohort analysis[J]. Seizure, 2015, 25:52-61. [7] 赵建彬, 陈菲菲. 基于文献分析的拉莫三嗪不良反应初步评估[J]. 中国医院药学杂志, 2013, 33(12): 1014-1015. [8] 刘立民, 江丹, 庞露, 等. 拉莫三嗪药动学及其影响因素研究进展[J]. 医药导报, 2013, 32(12): 1616-1621. [9] Shi Y W, Min F L, Zhou D, et al. HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions[J]. Neurology, 2017, 88(23):2183-2191. [10] Ko T M, Chung W H, Wei C Y, et al. Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome[J]. Journal of Allergy and Clinical Immunology, 2011, 128(6):1266-1276. [11] Hirsch L J, Arif H, Nahm E A, et al. Cross-sensitivity of skin rashes with antiepileptic drug use[J]. Neurology, 2008, 71(19):1527-1534. [12] Biton, Victor. Pharmacokinetics, toxicology and safety of lamotrigine in epilepsy[J]. Expert Opinion on Drug Metabolism & Toxicology, 2006, 2(6):1009-1018. |
| [1] | SUN Qiyue, ZHAO Ronghua, GUO Shanshan, BAO Lei, GENG Zihan, LI Shuran, XU Yingli, ZHANG Jingsheng, CUI Xiaolan, SUN Jing. Multiple pharmacological effects of Lingyang Ganmao Oral Liquid [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 127-131. |
| [2] | ZHAO Ronghua, SUN Jing, BAO Lei, GENG Zihan, TAO Xiali, ZHANG Jingsheng, PANG Bo, XU Yingli, CAO Shan, LI Shuran, GUO Shanshan, WANG Daohan, CUI Xiaolan. Mechanisms of Gegen Tang granules against viral pneumonia in mice based on immune regulation [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 132-136. |
| [3] | BAO Lei, GENG Zihan, LI Shuran, JI Zuen, ZHAO Ronghua, SUN Jing, GUO Shanshan, CUI Xiaolan. The critical role of TRP channels in the progression of viral pneumonia [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 137-140. |
| [4] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
| [5] | LI Jiaxin, LIU Huimin, QIAN Wenxiu, MA Ning, SONG Lili, LI Yubo. Nephrotoxic effects and usage of traditional Chinese medicines based on the Traditional Chinese Medicine Systems Toxicology Database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 173-180. |
| [6] | FAN Kaikai, WANG Cong, LIU Hongfeng, WANG Xiyong. Effects of clinical pharmacist interventions on usage of alanyl-glutamine injections in a hospital [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 181-184. |
| [7] | ZHANG Jian, FANG Huihua. Applicability of evaluation standards for use of traditional Chinese medicine injections for promoting blood circulation and removing blood stasis [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 185-189. |
| [8] | WANG Shan, XIE Bo, LIU Huimin, LI Zhihao. Adverse event signals for celecoxib based on FAERS database [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 190-194. |
| [9] | LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198. |
| [10] | XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203. |
| [11] | GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207. |
| [12] | FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210. |
| [13] | LI Na, GUO Jun, GUO Wenjia, LYU Yinyin, LI Caihong, MU Xiangdong. One case of delayed skin allergic reaction caused by asthma treated with omalizumab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 211-212. |
| [14] | CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218. |
| [15] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
